Supreme Court's mifepristone ruling is a temporary reprieve masking ongoing anti-abortion judicial strategy

Source: Reva Siegel, Mary Ziegler. "Is the Supreme Court’s abortion pill ruling actually a feint?." May 18, 2026. slate.com

The Gist

The authors argue that while the Supreme Court temporarily blocked a lower court's restriction on abortion pills, this doesn't mean the threat is over. They claim anti-abortion groups are using multiple legal strategies and the Trump administration to eventually ban these pills nationwide, while dishonestly framing their efforts as protecting women's health when they really want to punish people for having abortions.

Conclusion

The Supreme Court's temporary stay of the 5th Circuit's mifepristone ruling does not end the threat to abortion access, but rather represents a strategic pause in a broader campaign to impose national abortion restrictions through courts and administrative agencies

Premises

  1. Multiple ongoing cases in lower courts are challenging FDA regulation of mifepristone, some more ambitious than Louisiana's case
  2. The Trump administration's new FDA leadership has signaled willingness to restrict mifepristone access and is conducting a politicized safety review
  3. Justice Thomas and Alito's dissenting opinions reveal the Court is debating broader issues beyond standing, including applying the Comstock Act to criminalize mailing abortion pills
  4. The Louisiana case will return to the Supreme Court next year, and justices may intervene if the FDA doesn't reimpose restrictions
  5. Anti-abortion advocates have reframed their arguments as protecting women's health rather than fetal rights, but their true priority remains criminalizing abortion as evidenced by Louisiana's focus on punishing 'termination of unborn human life'
  6. States with the harshest abortion punishments invest least in actual healthcare for women and children, revealing the contradiction in their claimed concern for women's health

Assumptions

View this argument on LogicFirst.ai